Investor and Media Relations
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc.
anthony.marciano@seelostx.com
Offices
Seelos Therapeutics, Inc.
300 Park Avenue
New York, NY 10022
Incorporated
Nevada
Entity type
Corporation
Identifiers
CIK:1017491
IRS:870449967
Overview
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.
Stock History
On January 24, 2019, Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the completion of its previously disclosed merger with Apricus Biosciences, Inc.
Seelos Therapeutics, Inc. began trading on January 24, 2019 on The Nasdaq Capital Market under the ticker symbol “SEEL”.
Seelos maintains its headquarters in New York, New York and is led by Chairman, Founder, and Chief Executive Officer, Raj Mehra, Ph.D.
